sleepQ+ is an effective, low cost product
Two specific studies evaluating the safety of sleepQ+ for use in humans have been performed.
SENSITIVITY AND IRRITATION - Skin patch sensitivity study. Utilized fifty-four subjects by Cantor Research Laboratories, Inc of Blauvelt, NY, USA following the principles referenced in “Appraisal of the Safety of Chemicals in Food, Drugs and Cosmetics” published by the US FDA.
No adverse reactions of any kind were observed during the course of the study. It was concluded that the reversible oral adhesive gel is a non-primary irritant and a non-primary sensitizer.
TOXICITY - Cytotoxicity study
Performed by AMS Laboratories Pty Ltd of Silverwater, NSW, Australia according to ISO 10993-5 (2002) and AS/NZS 26961996. The reversible oral adhesive gel was found to be non-cytotoxic.
MADE IN THE US TO FDA MANUFACTURING STANDARDS AND REGISTERED WITH THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA), HEALTH CANADA AND MEDSAFE NZ.
Updated September 1 2021